Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
Study Information
Alliance Study ID: CALGB-19901
NCT Study ID (ClinicalTrials.gov): NCT00004857
Alliance Committee: Leukemia
Disease or Cancer Type: Leukemia & Myelodysplastic Syndromes (MDS)
Alliance Study Chair: Kanti R. Rai, MD
Status: COMPLETED
Study Description
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as alemtuzumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
PURPOSE: Phase II trial to study the effectiveness of fludarabine followed by alemtuzumab in treating patients who have chronic lymphocytic leukemia.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information